Navigation Links
SXC Health solutions announces strong fourth quarter and year end financial results
Date:3/5/2009

    -   Accretive acquisition of NMHC drives GAAP earnings per share growth
    -   Adjusted EBITDA $14.7 million in Q4 2008, up from $6.5 million in Q4
        2007

LISLE, IL, March 5 /PRNewswire-FirstCall/ - SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI, TSX: SXC), announces its financial results for the three- and twelve-month periods ended December 31, 2008. Financial references are in U.S. dollars unless otherwise indicated.

"2008 was a very rewarding year for SXC in which we delivered strong financial performance and built the platform to drive future growth," said Mark Thierer, President and CEO of SXC. "We made two strategic acquisitions, won substantial contracts in several target markets, added strong leadership in multiple areas of the business and grew the Company's reputation for technology innovation. In a challenging economic environment, our goal is to deliver revenue and earnings growth, and to continue our strategic push to redefine pharmacy benefit management as the industry's technology-enabled PBM. We believe we have the strategy, platform and people to deliver on these objectives in 2009."

    2008 Financial Highlights
    -------------------------
    -   Revenue was $862.9 million, compared to $93.2 million in fiscal 2007
    -   Gross profit was $115.5 million, compared to $53.6 million in fiscal
        2007
    -   Adjusted EBITDA(1) was $42.5 million compared, to $21.4 million in
        fiscal 2007
    -   GAAP net income increased to $15.1 million, or $0.65 per share
        (diluted), compared to $13.1 million, or $0.61 per share (diluted),
        in fiscal 2007
    -   Non-GAAP adjusted earnings per share(1) (diluted), which excludes the
        NMHC transaction-related amortization, was $0.89 for fiscal 2008 and
        $0.28 for Q4 2008
    -   Cash from operations was $41.6 million, compared to $22.1 million in
        fiscal 2007
    -   Adjusted prescription claim volume(1) for the PBM segment was
        8.4 million in Q4 2008
    -   Gross margin per adjusted prescription for the PBM segment was $3.34
        in Q4 2008
    -   Transaction processing volume for the HCIT segment was 115.3 million
        in Q4 2008

    2008 Corporate Highlights
    -------------------------
    -   Acquired National Medical Health Card Systems, Inc. (NMHC) to combine
        the highly complementary capabilities of SXC's PBM technology
        expertise and NMHC's leadership in traditional PBM services
    -   Acquired the assets of Zynchros, a leader in formulary management
        solutions
    -   New government sector sales activity generated in Tennessee, South
        Dakota, Washington and Arkansas
    -   Signed multi-million dollar deals with CVS/Caremark and UnitedHealth
        Group
    -   Announced five and a half year informedRx PBM service contracts with
        Health Plan of San Mateo and The University of Toledo

    Financial Review
    ----------------
    Revenue and gross profit segmented by PBM and HCIT was as follows:

    Three-months ended December 31, (unaudited, in thousands)

                     PBM                  HCIT              Consolidated
            --------------------- --------------------- ---------------------
             Q4 2008    Q4 2007    Q4 2008    Q4 2007    Q4 2008    Q4 2007
            ---------- ---------- ---------- ---------- ---------- ----------
    Revenue $ 269,802  $       -  $  22,964  $  23,552  $ 292,766  $  23,552
    Gross
     profit $  28,169  $       -  $   9,111  $  13,580  $  37,280  $  13,580
    Gross
     profit
     %          10.4%                 39.7%      57.7%      12.7%      57.7%



     Year ended December 31, (unaudited, in thousands)

                     PBM                  HCIT              Consolidated
            --------------------- --------------------- ---------------------
               2008       2007       2008       2007       2008       2007
            ---------- ---------- ---------- ---------- ---------- ----------
    Revenue $ 771,840  $       -  $  91,099  $  93,171  $ 862,939  $  93,171
    Gross
     profit $  69,507  $       -  $  45,979  $  53,576  $ 115,486  $  53,576
    Gross
     profit
     %           9.0%                 50.5%      57.5%      13.4%      57.5%

In reviewing the above tables, please note that the revenue for SXC's legacy informedRx business is captured in the HCIT segment for 2007 and in the PBM segment for 2008. As a result, the HCIT segment shows a slight decline in revenue for the three- and twelve-month periods ended December 31, 2008, due to the inclusion of some of the previously classified HCIT business now recorded in the new PBM segment.(2)

PBM revenue was $771.8 million for fiscal 2008. This figure reflects the addition of eight months of the NMHC business. NMHC contracts are recorded on a gross basis which equates to the prescription price paid by consumers plus an administrative fee.

Fiscal 2008 revenue for the HCIT segment consisted of $69.2 million of recurring revenue and $21.9 million of non-recurring revenue, compared to $70.7 million and $22.4 million in the corresponding periods of fiscal 2007. Recurring revenue consisted of transaction processing revenue of $52.8 million, compared to $54.3 million in fiscal 2007, and maintenance revenue of $16.4 million, compared to $16.5 million in fiscal 2007. The decline in transaction processing revenue is due to the fact that informedRx revenue is reported in the PBM segment for fiscal 2008 and was reported in the HCIT segment in fiscal 2007. Overall, recurring revenue accounted for 76% of HCIT revenue in fiscal 2008, consistent with 76% in fiscal 2007.

Fiscal 2008 non-recurring revenue consisted of system sales revenue of $8.4 million, consistent with $8.4 million last year, and professional service revenue of $13.5 million, compared to $14.0 million in fiscal 2007.

Q4 2008 revenue in the HCIT segment was comprised of $18.7 million of recurring revenue and $4.3 million of non-recurring revenue, compared to $18.3 million and $5.2 million, respectively, in Q4 2007. Recurring revenue consisted of transaction processing revenue of $14.6 million, up from $14.2 million last year, and maintenance revenue of $4.1 million, consistent with $4.1 million last year. Overall, recurring revenue accounted for 81% of HCIT revenue in Q4 2008, compared to 78% in Q4 2007.

Q4 2008 non-recurring revenue consisted of system sales revenue of $1.5 million, up from $1.2 million in Q4 2007, and professional service revenue of $2.8 million, down from $4.0 million in Q4 2007.

Product Development Costs

Fiscal 2008 product development expenses were $10.1 million compared to $10.2 million for fiscal 2007. Q4 2008 product development expenses were $2.7 million, compared to $2.2 million in Q4 2007. Product development remains a key priority for the Company as it develops enhancements to existing products and launches new offerings. Product development expenses include stock-based compensation cost of $0.3 million in both fiscal 2008 and fiscal 2007.

Selling, General and Administration ("SG&A") Costs

SG&A for fiscal 2008 was $68.8 million, compared to $26.5 million in fiscal 2007. In Q4 2008, SG&A costs were $21.5 million compared to $6.0 million in Q4 2007. The increase is largely attributable to the acquisition of NMHC and initiatives to expand the Company's sales and support capabilities.

Adjusted EBITDA(1)

Fiscal 2008 adjusted EBITDA was $42.5 million compared to $21.4 million in fiscal 2007. Q4 2008 adjusted EBITDA was $14.7 million compared to $6.5 million in Q4 2007. Q4 2008 adjusted EBITDA benefited from a $1.5 million non-recurring pick-up in the PBM segment's gross profit due to the Company's re-contracting efforts with drug manufacturers. This one-time improvement is in addition to strong performance in the year from the Company's efforts to drive better purchasing with the combined economies of scale created by the acquisition of NMHC. Adjusted EBITDA increased year-over-year due in part to the addition of the NMHC business, the addition of new business, improved purchasing efficiencies on prescription drugs, cost synergies generated from the acquisition, and offset in part by the addition of NMHC's operating expenses.

Income Taxes

Fiscal 2008 income tax expense was $5.2 million, representing an effective tax rate of 26%, compared to a $4.3 million, representing an effective tax rate of 25% for fiscal 2007. For Q4 2008, income tax expense was $1.7 million, representing an effective tax rate of 26%, compared to a $1.7 million income tax expense, representing an effective tax rate of 31%, in Q4 2007.

Net Income

The Company reported net income of $15.1 million for the year ended December 31, 2008, or $0.65 per share (fully-diluted), compared to net income of $13.1 million, or $0.61 per share (fully-diluted), for the year ended December 31, 2007. Q4 2008 net income was $5.0 million, or $0.20 per share (fully-diluted), compared to $3.8 million, or $0.18 in Q4 2007. Excluding the amortization of the NMHC acquisition (Non-GAAP Adjusted EPS(1)), the Company reported $0.89 per share (fully diluted) for the year-ended December 31, 2008 and $0.28 per share (fully diluted) in Q4 2008.

Cash from Operations

SXC continues to generate strong cash from operations. During fiscal 2008, SXC generated cash from operations of $41.6 million, compared to $22.1 million during fiscal 2007. The Company's quarterly cash flows can be impacted by the timing of pharmacy deposit and rebate payments it receives for certain customers. Net of pharmacy deposits and rebates payments, Q4 2008 and fiscal 2008 cash from operations were approximately $24.0 million and $48.6 million, respectively. This compares to cash from operations net of pharmacy deposits and rebates payments of $10.1 million and $21.5 million in the corresponding periods in fiscal 2007.

At December 31, 2008 and 2007, the Company has cash and cash equivalents totalling $67.7 million and $90.9 million, respectively. The decrease is primarily related to the cash paid for the acquisition of NMHC, and partially offset by the $46.5 million borrowed under a term loan. In Q4 2008, SXC grew its cash and cash equivalents by $16.1 million from $51.6 million at September 30, 2008.

2009 Financial Guidance

    With today's announcement, SXC is introducing guidance for 2009:
    -   Revenue of $1.2-$1.3 billion
    -   Gross profit of $140-$150 million
    -   Adjusted EBITDA of $51-$54 million
    -   Non-GAAP adjusted earnings per share(1) (fully-diluted) of $0.99-
        $1.08
        (excluding the NMHC transaction-related amortization)
    -   GAAP EPS (fully-diluted) of $0.77-$0.85
        (including all transaction-related amortization)

Notice of Conference Call

SXC will host a conference call on March 5, 2009 at 8:30AM (ET) to discuss its financial results. Mark Thierer, President and CEO, and Jeff Park, EVP and CFO will co-chair the call. All interested parties can join the call by dialing 416-644-3415 or 1-800-595-8550. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until Thursday, March 12, 2009 at midnight. To access the archived conference call, please dial 416-640-1917 or 1-877-289-8525 and enter the reservation code 21297791 followed by the number sign.

A live audio webcast of the conference call will be available at www.sxc.com and www.newswire.ca. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available for 365 days.

(1) Non-GAAP Financial Measures

SXC reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP"). SXC's management also evaluates and makes operating decisions using various other measures. Two such measures are adjusted earnings per share, and adjusted EBITDA, which are non-GAAP financial measures. SXC's management believes that these measures provide useful supplemental information regarding the performance of SXC's business operations.

Adjusted earnings per share is a non-GAAP measure which takes earnings per share and adds back the impact of amortization expense related to the acquisition of NMHC, net of tax. Acquisition-related amortization expense is a non-cash expense arising from the acquisition of intangible assets in connection with the acquisition. SXC excludes acquisition-related amortization expense from non-GAAP adjusted earnings per share because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of SXC business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets will contribute to revenue in the future period presented and periods beyond that and should also note that such expense will recur in future periods. The 2009 guidance of adjusted earnings per share was computed by taking the Company's GAAP earnings per share guidance and adding back the expected impact of acquisition-related amortization expense, net of tax.

Adjusted EBITDA is a non-GAAP measure that management believes is a useful supplemental measure of operating performance prior to net interest income (expense), income taxes, depreciation, amortization, stock-based compensation, and certain other one-time charges. Management believes it is useful to exclude depreciation, amortization and net interest income (expense) as these are essentially fixed amounts that cannot be influenced by management in the short term. In addition, management believes it is useful to exclude stock-based compensation as this is not a cash expense. Lastly, certain other one-time charges (including losses on disposals of capital assets) are excluded as these are not considered to be recurring items.

Adjusted prescription volume equals SXC's Mail Service prescriptions multiplied by three, plus its retail and specialty prescriptions. The Mail Service prescriptions are multiplied by three to adjust for the fact that they typically include approximately three times the amount of product days supplied compared with retail prescriptions.

Management believes that adjusted earnings per share, adjusted EBITDA and adjusted prescription volume provide useful supplemental information to management and investors regarding the performance of the Company's business operations and facilitate comparisons to its historical operating results. Management also uses this information internally for forecasting and budgeting as it believes that the measures are indicative of the Company's core operating results. Note however, that these items are performance measures only, and do not provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures should not be considered as a substitute for measures of financial performance in accordance with GAAP, and investors and potential investors are encouraged to review the reconciliation of adjusted earnings per share and adjusted EBITDA.

Adjusted earnings per share and adjusted EBITDA do not have standardized meanings prescribed by GAAP. The Company's method of calculating these items may differ from the methods used by other companies and, accordingly, it may not be comparable to similarly titled measures used by other companies. Reconciliation of adjusted EBITDA to net income and adjusted net income to net income is shown below:

                                 For the three              For the 12
                                  months ended             months ended
                                  December 31,              December 31,
                               2008         2007         2008         2007
                          ------------ ------------ ------------ ------------
                                      (unaudited) (in thousands)

    Adjusted EBITDA       $    14,679  $     6,527  $    42,474  $    21,396

    Amortization of NMHC
     Intangibles               (2,680)           -       (7,769)           -

    Depreciation &
     Amortization              (2,308)      (1,448)      (8,211)      (5,578)

    Stock-Based Compensation   (1,074)        (790)      (4,080)      (3,040)

    Net Loss on Disposal of
     Assets                         -            -            -         (133)

    Other Income (expense)       (734)         (18)        (719)         221

    Interest (Expense)
     Income, Net               (1,193)       1,228       (1,391)       4,578

    Income Tax Expense         (1,740)      (1,722)      (5,191)      (4,298)
                               -------      -------      -------      -------

    Net Income            $     4,950  $     3,777  $    15,113  $    13,146
                                -----        -----       ------       ------
                                -----        -----       ------       ------



    Non-GAAP Adjusted Earnings Per Share             For the 3    For the 12
                                                   months ended  months ended
                                                   Dec 31, 2008  Dec 31, 2008
                                                   ------------  ------------
                                                           (unaudited)
                                                     (in thousands, except
                                                         per share data)
    Net Income                                      $     4,950  $    15,113

    Amortization of NMHC Intangibles (Net of Taxes)       1,983        5,780
                                                          -----        -----

    Adjusted Net-Income                                   6,933       20,893
                                                          -----       ------
                                                          -----       ------

    Adjusted EPS (diluted)                          $      0.28  $      0.89

(2) On April 30, 2008, SXC closed the acquisition of NMHC. As a result, SXC has introduced some new segmentation and presentation of its financial results. Revenue is now segmented into two groups: Pharmacy Benefits Management ("PBM") which includes informedRx as well as mail-order and specialty pharmacies, and Health Care Information Technology ("HCIT"). SXC records PBM revenue from NMHC exclusively on a gross basis which equates to the prescription price paid by consumers plus an administrative fee. The HCIT business records revenue only on the basis of the administrative fee; drug ingredient cost is not included in revenues or cost of claims.

The net effect is that SXC's year-over-year revenues have increased dramatically while gross profit margin and adjusted EBITDA have increased in absolute dollar terms, but have declined as a percentage of total sales. These changes do not affect profitability on an absolute dollar or per share basis.

About SXC Health Solutions Corp.

SXC Health Solutions Corp. is a leading provider of pharmacy benefits management (PBM) services and Health Care Information Technology (HCIT) solutions to the healthcare benefits management industry. The Company's product offerings and solutions combine a wide range of software applications, application service provider (ASP) processing services and professional services, designed for many of the largest organizations in the pharmaceutical supply chain, such as Federal, provincial, and, state and local governments, pharmacy benefit managers, managed care organizations, retail pharmacy chains and other healthcare intermediaries. SXC is headquartered in Lisle, Illinois with 13 locations in the US and Canada. For more information please visit www.sxc.com.

Forward-Looking Statements

Certain statements included herein, including those that express management's expectations or estimates of our future performance, constitute "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause our actual financial results, performance, or achievements to be materially different from our estimated future results, performance or achievements expressed or implied by those forward-looking statements. Numerous factors could cause actual results to differ materially from those in the forward-looking statements, including without limitation, our ability to achieve increased market acceptance for our product offerings and penetrate new markets; consolidation in the healthcare industry; the existence of undetected errors or similar problems in our software products; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; our ability to compete successfully; potential liability for the use of incorrect or incomplete data; the length of the sales cycle for our healthcare software solutions; interruption of our operations due to outside sources; our dependence on key customers; maintaining our intellectual property rights and litigation involving intellectual property rights; our ability to obtain, use or successfully integrate third-party licensed technology; compliance with existing laws, regulations and industry initiatives and future change in laws or regulations in the healthcare industry; breach of our security by third parties; our dependence on the expertise of our key personnel; our access to sufficient capital to fund our future requirements; and potential write-offs of goodwill or other intangible assets. This list is not exhaustive of the factors that may affect any of our forward-looking statements. Other factors that should be considered are discussed from time to time in SXC's filings with the U.S. Securities and Exchange Commission, including the risks and uncertainties discussed in our 2007 Annual Report on Form 10-K and 2008 Form 10-Qs, which are available at www.sec.gov. Investors are cautioned not to put undue reliance on forward-looking statements. All subsequent written and oral forward-looking statements attributable to SXC or persons acting on our behalf are expressly qualified in their entirety by this notice. We disclaim any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Certain of the assumptions made in preparing forward-looking information and management's expectations include: maintenance of our existing customers and contracts, our ability to market our products successfully to anticipated customers, the impact of increasing competition, the growth of prescription drug utilization rates at predicted levels, the retention of our key personnel, our customers continuing to process transactions at historical levels, that our systems will not be interrupted for any significant period of time, that our products will perform free of major errors, our ability to obtain financing on acceptable terms and that there will be no significant changes in the regulation of our business.

                         SXC HEALTH SOLUTIONS CORP.
                         Consolidated Balance Sheets
              (in thousands of U.S. dollars, except share data)


                                                             December 31,
                                                    -------------------------
                                                         2008         2007
                                                    ------------ ------------

    ASSETS
    Current assets
      Cash and cash equivalents                     $    67,715  $    90,929
      Restricted cash                                    12,498            -
      Accounts receivable, net of allowance for
       doubtful accounts of $3,570 (December 31,
       2007 - $605)                                      80,531       17,990
      Rebates receivable                                 29,586            -
      Unbilled revenue                                       73        1,195
      Prepaid expenses and other                          4,382        2,361
      Inventory                                           6,689          242
      Income tax recoverable                              1,459        1,073
      Deferred income taxes                              10,219        3,246
                                                    ------------ ------------
      Total current assets                              213,152      117,036

    Property and equipment, net of accumulated
     depreciation of $19,449 (December 31, 2007
     - $13,004)                                          20,756       13,629
    Goodwill                                            143,751       15,996
    Other intangible assets, net of accumulated
     amortization of  $14,099 (December 31, 2007
     - $4,734)                                           46,406        9,661
    Deferred financing charges                            1,481            -
    Deferred income taxes                                 1,323        3,157
    Other assets                                          1,474            -
                                                    ------------ ------------
    Total assets                                    $   428,343  $   159,479
                                                    ------------ ------------
                                                    ------------ ------------


    LIABILITIES AND SHAREHOLDERS' EQUITY

    Current liabilities
      Accounts payable                              $     8,302  $     1,344
      Customer deposits                                  11,875            -
      Salaries and wages payable                         15,681        2,909
      Accrued liabilities                                32,039        4,807
      Pharmacy benefit management rebates payable        36,326        2,766
      Pharmacy benefit claim payments payable            51,406        2,059
      Deferred revenue                                    7,978        6,750
      Current portion of long-term debt                   3,720            -
                                                    ------------ ------------
        Total current liabilities                       167,327       20,635

    Long-term debt, less current installments            43,920            -
    Deferred income taxes                                15,060        1,091
    Deferred lease inducements                            3,217        3,222
    Deferred rent                                         1,461        1,087
    Other liabilities                                     3,195          987
                                                    ------------ ------------
       Total liabilities                                234,180       27,022
                                                    ------------ ------------

    Shareholders' equity
      Common stock: no par value, unlimited shares
       authorized;
        24,103,032 shares issued and outstanding at
         December 31, 2008 (December 31, 2007
         - 20,985,934 shares)                           146,988      103,520
      Additional paid-in capital                         11,854        8,299
      Retained earnings                                  35,751       20,638
      Accumulated other comprehensive income               (430)           -
                                                    ------------ ------------
        Total shareholders' equity                      194,163      132,457

                                                    ------------ ------------
    Total liabilities and shareholders' equity      $   428,343  $   159,479
                                                    ------------ ------------
                                                    ------------ ------------



                         SXC HEALTH SOLUTIONS CORP.
                    Consolidated Statements of Operations
              (in thousands of U.S. dollars, except share data)

                              Three months ended            Years ended
                                  December 31,              December 31,
                               2008         2007         2008         2007
                          ------------ ------------ ------------ ------------
    Revenue:
      PBM                 $   269,802  $         -  $   771,840  $         -
      HCIT:
        Transaction
         processing            14,606       14,167       52,773       54,273
        Maintenance             4,059        4,145       16,397       16,476
        Professional
         services               2,787        4,030       13,480       14,031
        System sales            1,512        1,210        8,449        8,391
                          ------------ ------------ ------------ ------------
    Total revenue             292,766       23,552      862,939       93,171

    Cost of revenue:
      PBM                     241,633            -      702,333            -
      HCIT                     13,853        9,972       45,120       39,595
                          ------------ ------------ ------------ ------------
    Total cost of revenue     255,486        9,972      747,453       39,595
                          ------------ ------------ ------------ ------------
    Gross profit               37,280       13,580      115,486       53,576

    Expenses:
      Product development
       costs                    2,680        2,207       10,105       10,206
      Selling, general and
       administrative          21,501        6,031       68,792       26,532
      Depreciation of
       property and
       equipment                1,394          657        4,810        2,476
      Amortization of
       intangible assets        3,088          396        9,365        1,584
      Net loss on disposal
       of capital assets            -            -            -          133
                          ------------ ------------ ------------ ------------
                               28,663        9,291       93,072       40,931

                          ------------ ------------ ------------ ------------
    Operating income            8,617        4,289       22,414       12,645

    Interest income              (540)      (1,255)      (2,749)      (4,690)
    Interest expense            1,733           27        4,140          112
                          ------------ ------------ ------------ ------------
      Net interest expense
       (income)                 1,193       (1,228)       1,391       (4,578)


    Other (income) expense        734           18          719         (221)
                          ------------ ------------ ------------ ------------
    Income before income
     taxes                      6,690        5,499       20,304       17,444

    Income tax expense
     (benefit):
      Current                    (469)       2,225        4,866        5,258
      Deferred                  2,209         (503)         325         (960)
                          ------------ ------------ ------------ ------------
                                1,740        1,722        5,191        4,298

                          ------------ ------------ ------------ ------------
    Net income            $     4,950  $     3,777  $    15,113  $    13,146
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------

    Earnings per share:
     Basic                $      0.21  $      0.18  $      0.66  $      0.63
     Diluted              $      0.20  $      0.18  $      0.65  $      0.61

    Weighted average number
     of shares used in
     computing earnings per
     share:

      Basic                24,055,909   20,924,313   22,978,466   20,755,375
      Diluted              24,603,214   21,405,286   23,413,011   21,562,754



                         SXC HEALTH SOLUTIONS CORP.
                    Consolidated Statements of Cash Flows
                       (in thousands of U.S. dollars)

                              Three months ended            Years ended
                                  December 31,              December 31,
                               2008         2007         2008         2007
                          ------------ ------------ ------------ ------------

    Cash flows from
     operating activities:
      Net income          $     4,950  $     3,777  $    15,113  $    13,146
      Adjustments to
       reconcile net income
       to net cash provided
       by operating
       activities:
        Stock-based
         compensation           1,074          790        4,080        3,040
        Depreciation of
         property and
         equipment              1,900        1,052        6,615        3,994
        Amortization of
         intangible assets      3,088          396        9,365        1,584
        Deferred lease
         inducements and
         rent                     (98)         (16)        (304)         452
        Loss on disposal of
         property and
         equipment                  -            -            -          133
        Deferred income
         taxes                  2,209       (1,024)         325         (960)
        Tax benefit on
         option exercises           1          (10)        (798)      (2,405)
        Loss (gain) on
         foreign exchange         201           (2)         187         (152)
      Changes in operating
       assets and liabilities,
       net of effects from
       acquisition:
        Accounts receivable       147          204        8,005       (3,678)
        Rebates receivable     (5,400)           -       (2,383)           -
        Restricted cash         5,292            -          632            -
        Unbilled revenue        1,019           94        1,122          781
        Prepaid expenses         (808)        (345)         107         (335)
        Inventory                  88           40          (83)          18
        Income tax
         recoverable             (941)      (1,079)         677       (1,073)
        Income taxes payable        -        2,405            -        1,811
        Accounts payable        1,182         (337)       1,678          689
        Accrued liabilities     9,297          940        4,845          685
        Pharmacy benefit
         claim payments
         payable               (9,406)        (228)      (8,357)        (905)
        Pharmacy benefit
         management rebates
         payable                6,385          500        1,305        1,593
        Deferred revenue        2,694        5,032        2,301        3,731
        Customer deposits      (1,926)           -       (2,996)           -
        Other                      37            -          148            -
                          ---------------------------------------------------
          Net cash provided
           by operating
           activities          20,985       12,189       41,584       22,149

    Cash flows from
     investing activities:
      Purchases of property
       and equipment           (2,440)        (941)      (8,410)      (7,651)
      Lease inducements
       received                     -            -          373          391
      Acquisitions, net
       of cash acquired        (2,207)           -     (104,769)           -
      Proceeds from disposal
       of property and
       equipment                    -            -            -            9
                          ------------ ------------ ------------ ------------
      Net cash used in
       investing activities    (4,647)        (941)    (112,806)      (7,251)

    Cash flows from
     financing activities:
      Issuance of long-term
       debt                         -            -       48,000            -
      Payment of financing
       costs                        -            -       (1,792)           -
      Repayment of long-term
       debt                      (120)           -         (360)           -
      Proceeds from exercise
       of options                 109          328        1,549        2,531
      Tax benefit on option
       exercises                   (1)          10          798        2,405
                          ------------ ------------ ------------ ------------
        Net cash (used)
         provided by
         financing
         activities               (12)         338       48,195        4,936

    Effect of foreign
     exchange on cash
     balances                    (201)           2         (187)         152

                          ------------ ------------ ------------ ------------
    Increase(decrease) in
     cash and cash
     equivalents               16,125       11,588      (23,214)      19,986

    Cash and cash
     equivalents,
     beginning of period       51,590       81,114       90,929       70,943

                          ------------ ------------ ------------ ------------
    Cash and cash
     equivalents,
     end of period         $   67,715  $    92,702  $    67,715  $    90,929
                          ------------ ------------ ------------ ------------
                          ------------ ------------ ------------ ------------


'/>"/>
SOURCE SXC Health Solutions Corp.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. AUDIO from Medialink and UnitedHealthcare: Maintaining Your Health Coverage
2. RoundTable Appoints Senior Healthcare Executives
3. Bob Greene, Americas Personal Trainer, Brings His Secrets Of Healthy Living To Discovery Health
4. National Center for Creative Aging Presents Creativity Matters Symposium on Health, Wellness, and the Arts
5. NACDS Commends Obama's Shared Commitment on Accessible, Quality and Affordable Healthcare
6. DW Healthcare Partners and BB&T Capital Partners Invest in Career Step, LLC
7. AAPS Doctors: White House Healthcare Prom Invitations Lost in the Mail
8. HealthFitness Announces Year-End 2008 Financial Results
9. Abbott to Present at Cowen Annual Health Care Conference
10. Illinois Advocates Take on Health Insurance Industry
11. Association for Healthcare Philanthropy Opposes Limits on Charitable Tax Deductions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 bioLytical Laboratories, un líder mundial en test rápidos ... HIV Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la ...
(Date:12/2/2016)... GARDENS, N.Y. , Dec. 2, 2016  LifeVac, ... will be included in the Emergency Response Training and ... are very excited to have LifeVac become part of ... Lih , Founder and CEO of LifeVac. "Having an ... LifeVac safely and effectively will help leverage our efforts ...
(Date:12/2/2016)... India , December 2, 2016 ... report "In Vitro Diagnostics/IVD Market by Product (Instruments, ... Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) ... global market is valued at USD 60.22 Billion ... at a CAGR of 5.5% during the forecast ...
Breaking Medicine Technology: